

Abstract of the Invention

The present invention relates to the use of non-primate mammalian cell lines having substantially no endogenous retroviral sequences as producer and packaging
5 lines for preparation of human serum-resistant retroviral vector particles with improved safety for use in gene therapy applications. In a preferred embodiment, the cell line used in the present invention is the α -galactosyl(α Gal)-positive cell ferret brain cell line
10 designated as Mpf or a cell line having those identifying characteristics of the Mpf cell line suitable for the practice of the invention.